|
1）Finch C. Regulation of iron balance in humans. Blood. 1994; 84: 1697-702
|
|
|
|
2）Camaschella C. Iron and hepcidin: a story of recycling and balance, Ham-Wasserman manuscript. American Society of Hematology. Hematology. 2013; 1-8
|
|
|
|
|
|
3）Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron flux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-3
|
|
|
|
|
4）Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol. 2011; 54: 173-81
|
|
|
|
|
|
5）Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation on signals, and signaling cross talk. Cytokine Growth Fact Rev. 2005; 16: 251-63
|
|
|
|
|
|
6）Mleczko- Sanecke K, Rched T, Rita da Silba A, et al. Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood. 2014; 123: 1574-85
|
|
|
|
|
|
7）Hosoki T, Ikuta K, Shomonaka Y, et al. Heterogeneous expressions of hepcidin isoforms in hepatoma-derived cells using simultaneous LC-MS/MS. Proteomics Clin Appl. 2009; 3: 1256-64
|
|
|
|
|
|
8）Core AB, Canali S, Babitt JL. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 2014; Doi: 10.3389/fphar.2014.00104
|
|
|
|
|
|
9）Enns CA, Ahmed R, Wang J, et al. Increased iron loading induces BMP6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway. PLos One. 2013; 8: e60534. Doi 10.1371/journal.pone.0060534. Equb 2013 Apr 2
|
|
|
|
|
|
10）Sasaki Y, Shimonaka Y, Ikuta K, et al. Hepcidin production in response to iron is controlled by monocyte-derived humoral factors. Int J Hematol. 2014; 99: 12-20
|
|
|
|
|
11）Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005; 105: 376-81
|
|
|
|
|
|
12）Worthen CA, Enns CA. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front Pharmacol. 2014; 5: 1-8. doi 10.3389/fphar. 2014.00034
|
|
|
|
|
|
13）Pippard MJ, Callender ST, Warner GT, et al. Iron absorption and loading in beta-thalassaemia intermedia. Lancet. 1979; 2: 819-21
|
|
|
|
|
|
14）Pak M, Lppex MA, Gabayan V, et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108: 3730-5
|
|
|
|
|
|
15）Tanno T, Ghanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine. 2007; 13: 1096-101
|
|
|
|
|
|
16）Tanno T, Porayaette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114: 181-6
|
|
|
|
|
|
17）Kauts L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics. 2014; doi: 10.1038/ng.2996
|
|
|
|
|
|
18）Seldin MM, Peterson JM, Byerly MS, et al. Myonectin(CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostatis. J Biol Chem. 2012; 287: 11968-80
|
|
|
|
|
|
19）Theil EC. Iron homeostasis and nutritional iron deficiency. J Nutr. 2011; 141: 724S-728S
|
|
|
|
|
|
20）Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-iron transporter. Nature. 1997; 388: 482-8
|
|
|
|
|
|
21）Gunshin H, Allerson CR, Polycarpou-Schwartz M, et al. Iron-dependent regulation of the divalent metal transporter. FEBS Lett. 2011; 509: 309-16
|
|
|
|
|
|
22）Yanatori I, Yasui Y, Tabuchi M, et al. Chaperone protein involved in transmembrane transport of iron. Biochem J. 2014; 462: 25-37. doi: 10.1042/BJ20140225
|
|
|
|
|
|
23）Laftah AH, Latunde-Dada GO, Fakih S, et al. Haem and folate transport by proton-coupled folate transporte/haem carrier protein 1 (SLC46A1). Br J Nutr. 2009; 101: 1150-6
|
|
|
|
|
|
24）Theil EC, Chen H, NIranda C, et al. Absoprtion of iron from ferritin is independent of heme iron and ferrous salts in women and tat intestinal segments. J Nutr. 2012; 142: 478-83
|
|
|
|
|
|
25）Asiam MF, Frazer DM, Faria N, et al. Ferriportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice. FASEB J. 2014; 28: 3671-8. doi: 10.1096/fj.14251520.qub 2014 Apr 28
|
|
|
|
|
|
26）Fung E, Sugitano P, Hsu J, et al. High throughput screening of small molecules identifies hepcidin antagosints. Mol Pharmacol. 2013; 83: 681-90
|
|
|
|
|
|
27）Altamura S, DʼAlesio F, Selle B, et al. A novel TMPRSS6 mutation that prevents protease auto-activation cause IRIDA. Biochem J. 2010; 431: 363-71. Doi. 10.1042/BJ2010068
|
|
|
|
|
|
28）Camaschella C. How I manage patients with atypical microcytic anemia. Brit J Hematol. 2012; 160: 12-24
|
|
|
|
|
|
29）Hershko C, Gragan G, Bates GW, et al. Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978; 40: 255-63
|
|
|
|
|
|
30）Brisott P, Ropert M, Le Lan C, et al. Non-transferrin bound iron: a key role in iron overload in overload and iron toxicity. Biochim Biophys Acta. 2012; 1820: 403-10
|
|
|
|
|
|
31）NCCNガイドライン® 骨髄異形成症候群 2014年第2版 デイスカッション
|
|
|
|
|
|
32）Pinto JP, Arezes J, Dias V, et al. Physiological implications of NTBI uptake by T lymphocytes. Frontiers in Pharmacology. 2014; 5: 1-15
|
|
|
|
|
|
33）Gosriwatana I, Loreal O, Lu S, et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999; 273: 212-20
|
|
|
|
|
|
34）Sasaki K, Ikuta K, Tanaka H, et al. Improved quantification for non-transferrin bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol Med Rep. 2011; 4: 913-8
|
|
|
|
|
|
35）Ito S, Ikuta K, Kato D, et al. Non-transferrin-bound iron assay system utilizing a conventional automated analyzer. Clin Chim Acta. 2014; pii: S0009-8981(14) 300-303. Doi: 10.1016/j.cca.2014.07.013
|
|
|
|
|
|
36）Gatterman N, Finelli C, Fomi GL, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndrome. Results from the large-1- year EPIC study. Leuk Res. 2010; 34: 1143-50
|
|
|
|
|
|
37）Msinous III AG, Tanner R, Hujihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Brit J Haematol. 2014; doi: 10.1111/bjh.13053
|
|
|
|
|
|
38）Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO) Clinicaltrials.gov. NCT00940602
|
|
|
|
|